ENOXIMONE IN NEWBORNS WITH REFRACTORY POSTOPERATIVE LOW-OUTPUT STATES (LOS)

被引：8

作者：

HAUSDORF, G

FRIEDEL, N

BERDJIS, F

DIETERICH, HA

FELL, JJ

DRESSLER, HT

WERNEYER, A

HETZER, R

LANGE, PE

机构：

[1] German Heart Center, Berlin

[2] Merell Dow Research Institute, Rüsselsheim

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1992年 / 6卷 / 06期

关键词：

CONGENITAL HEART DISEASE; POSTOPERATIVE CARDIAC LOW-OUTPUT STATE; CATECHOLAMINES; ENOXIMONE; NEONATES;

D O I：

10.1016/1010-7940(92)90148-Q

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Enoximone was administered to 16 newborns with postoperative, catecholamine-refractory cardiac low-output states in addition to high-dose catecholamine treatment. Haemodynamic changes were assessed at baseline and during treatment. Haemodynamic parameters were improved in 12 newborns ("responders"), 9 of these survived. Three responders died; one from cardiac low-output and 2 from uncorrectable congenital heart disease verified by autopsy. Four newborns did not respond to enoximone therapy ("non-responders") and died. The haemodynamic effects of enoximone were characterized by an increase in cardiac index (+160%, P < 0.0008), and a fall in right (-26%, P < 0.0004) and left (-34%, P < 0.003) atrial pressures. It is concluded that enoximone can be an effective agent in the treatment of cardiac low-output states refractory to high-dose catecholamines in neonates up to 7 months old.

引用

页码：311 / 317

页数：7

共 22 条

[1]

Anderson R.H., McArtney F.J., Shinebourne E.A., Tyan M., Pediatric cardiology, pp. 509-540, (1987)

[2]

Berner M., Jaccard C., Oberhansli I., Rouge J.C., Friedli B., Hemodynamic effects of amrinone in children after cardiac surgery, Intensive Care Med, 16, pp. 85-88, (1990)

[3]

Boldt J., Dieterich H.A., Kling D., Hempelmann G., Hemodynamic effects of enoximone in open cardiac surgery, J Cardiovasc Pharmacol, 14, pp. 50-56, (1989)

[4]

Boldt J., Kling D., Schuhmann E., Scheld H.H., Hempelmann G., Der neue Phosphodiesterasehemmer Enoximon: Ein-satzmöglichkeiten im Rahmen herzchirurgischer Eingriffe, Herz, 13, pp. 335-342, (1988)

[5]

Bristow M.R., Ginsburg R., Minoke W., Decreasing catecholamine sensitivity and betaadrenergic receptor density in failing human hearts, N Engl J Med, 307, pp. 205-211, (1982)

[6]

Bristow M.R., Lee E.M., Gilbert E.M., Renlund D.G., Hegewald M.G., Hershberger R.E., O'Connell J.B., Use of enoximone in patients awaiting cardiac transplant, Br J Clin Pract, 42, pp. 69-72, (1989)

[7]

Colucci W.S., Wright R.F., Braunwald E., New positive inotropic agents in the treatment of congestive heart failure, New Engl J Med, 314, pp. 349-358, (1986)

[8]

Crawford M.H., Intravenous use of enoximone, Am J Cardiol, 60, pp. 42C-45C, (1987)

[9]

Dage R.C., Roebel L.E., Hsieh C.P., Weiner D.L., Woodward J.K., Cardiovascular properties of a new cardiotonic agent, MDL 17 043, J Cardiovasc Pharmacol, 4, pp. 500-508, (1982)

[10]

Dubois-Rande J.L., Loisance D., Duval A.M., Delauze P., Lel-louche D., Hillion M.L., Tarral A., Castaigne A., Enoximone, a pharmacological bridge to transplantation, Br J Clin Practice, 42, pp. 73-79, (1988)

← 1 2 3 →